Responses
Clinical and epidemiological research
Extended report
Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes
Compose a Response to This Article
Other responses
No responses have been published for this article.